134 related articles for article (PubMed ID: 38752476)
1. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
7. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
Haskoloğlu Ş; Köstel Bal S; İslamoğlu C; Altun D; Kendirli T; Doğu EF; İkincioğulları A
Pediatr Transplant; 2018 Nov; 22(7):e13266. PubMed ID: 29992714
[TBL] [Abstract][Full Text] [Related]
8. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
9. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
Holtick U; Herling M; Pflug N; Chakupurakal G; Leitzke S; Wolf D; Hallek M; Scheid C; Chemnitz JM
Ann Hematol; 2017 Mar; 96(3):479-487. PubMed ID: 27909887
[TBL] [Abstract][Full Text] [Related]
10. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Huttunen P; Taskinen M; Vettenranta K
Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
[TBL] [Abstract][Full Text] [Related]
12. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.
Laberko A; Sultanova E; Gutovskaya E; Radygina S; Deripapa E; Kantulaeva A; Trakhtman P; Brilliantova V; Starichkova J; Shcherbina A; Maschan M; Maschan A; Balashov D
J Clin Immunol; 2020 Aug; 40(6):861-871. PubMed ID: 32602054
[TBL] [Abstract][Full Text] [Related]
14. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
Wu W; Xue N; Yang H; Gao P; Guo J; Han D
J Pediatr Hematol Oncol; 2023 Oct; 45(7):370-376. PubMed ID: 37526377
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
20. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Ruutu T; Volin L; Beelen DW; Trenschel R; Finke J; Schnitzler M; Holowiecki J; Giebel S; Markiewicz M; Uharek L; Blau IW; Kienast J; Stelljes M; Larsson K; Zander AR; Gramatzki M; Repp R; Einsele H; Stuhler G; Baumgart J; Mylius HA; Pichlmeier U; Freund M; Casper J
Haematologica; 2011 Sep; 96(9):1344-50. PubMed ID: 21659356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
